Pharmaceutical compositions
The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.
1. A pharmaceutical composition comprising:
a) an inner extended release core, wherein the inner extended release core is a formulation comprising metformin hydrochloride, a swellable and/or extended release polymer, and one or more further excipients;
b) an intermediate seal coating; and
c) an outer immediate release coating, wherein the outer immediate release coating is a film coat formulation comprising the SGLT2-inhibitor 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a film-coating agent, a plasticizer, and, optionally, a glidant.
2. The pharmaceutical composition according to claim 1 , wherein the film-coating agent is hydroxypropyl methylcellulose.
3. The pharmaceutical composition according to claim 1 , wherein the plastizicer is polyethylene glycol.
4. The pharmaceutical composition according to claim 1 , wherein the plastizicer is propylene glycol.
5. The pharmaceutical composition according to claim 1 , wherein the optional glidant is talc.
6. The pharmaceutical composition according to claim 1 , wherein the seal coating comprises a film-coating agent, a plasticizer, and, optionally, a glidant, one or more pigments and/or colors.
7. The pharmaceutical composition according to claim 1 , wherein the metformin hydrochloride is present in a unit dosage strength of 500, 750, 850, 1000 or 1500 mg.
8. The pharmaceutical composition according to claim 1 , wherein the SGLT-2 inhibitor is present in a unit dosage strength of 5, 10, 12.5 or 25 mg.
9. The pharmaceutical composition according to claim 1 , which is a tablet for oral administration.
10. The tablet according to claim 9 further comprising an outer film over-coat.
11. The tablet according to claim 10 , wherein the outer film over-coat comprises a film-coating agent, a plasticizer, and, optionally, a glidant, one or more pigments and/or colors.
12. A method of using the pharmaceutical composition according to claim 1 for treating, preventing, slowing the progression, or delaying the onset of metabolic diseases either in type 2 diabetes patients who have not been previously treated with an antihyperglycemic agent, or
in type 2 diabetes patients with insufficient glycemic control despite therapy with one or two conventional antihyperglycemic agents selected from metformin, sulphonylureas, thiazolidinediones, glinides, alpha-glucosidase blockers, GLP-1 or GLP-1 analogues, and insulin or insulin analogues; comprising administering the composition of claim 1 to said patient.
13. The method of claim 12 , wherein the metabolic disease is type 2 diabetes mellitus and conditions related thereto.
14. The pharmaceutical composition according to claim 2 , wherein the hydroxypropyl methylcellulose is Hypromellose 2910, Methocel E5, or Methocel E15.
15. The pharmaceutical composition according to claim 3 , wherein the polyethylene glycol is Macrogol 400, 6000 or 8000.
16. The pharmaceutical composition according to claim 1 , wherein the dosage strength is 5 mg of the SGLT2 inhibitor and 1000 mg metformin hydrochloride.
17. The pharmaceutical composition according to claim 1 , wherein the dosage strength is 10 mg of the SGLT2 inhibitor and 1000 mg metformin hydrochloride.
18. The pharmaceutical composition according to claim 1 , wherein the dosage strength is 12.5 mg of the SGLT2 inhibitor and 1000 mg metformin hydrochloride.
19. The pharmaceutical composition according to claim 1 , wherein the dosage strength is 25 mg of the SGLT2 inhibitor and 1000 mg metformin hydrochloride.
20. The pharmaceutical composition according to claim 1 , wherein the extended release material comprises poly(ethylene oxide) and/or hydroxypropyl methylcellulose (HPMC).
21. The pharmaceutical composition according to claim 6 , wherein the film coating agent is a mixture of hydroxypropylcellulose and hydroxypropyl methylcellulose.
22. The pharmaceutical composition according to claim 1 , wherein the outer immediate release coating comprises the SGLT2 inhibitor and 1-[(4-methyl-quinazolin-2- yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine.